In:
International Journal of Gynecologic Cancer, BMJ, Vol. 32, No. 10 ( 2022-10), p. 1283-1288
Abstract:
The objective of this systematic review was to assess the incidence of lymph node metastasis in patients with clinically presumed early-stage low-grade serous ovarian cancer that underwent primary surgical treatment. Methods This study was registered in PROSPERO (CRD42022308923). A systematic literature review was conducted following the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) checklist. PubMed/MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Ovid, and Scopus databases were searched since inception and up to March 2022. The inclusion criteria were: pathological confirmation of low-grade serous ovarian cancer (clinically presumed FIGO 2014 stages I-IIA at time of surgery) that underwent primary surgical treatment, including pelvic and/or para-aortic lymph node dissection. Results The search identified 3763 articles; 59 were considered potentially eligible after removing duplicates, and eight studies finally met the selection criteria. In total, 35 of 277 (12.6%) patients had lymph node metastasis, and only four studies reported upstaging due to lymph node metastasis in 16 of 153 (10.5%) patients. None of the eight studies included reported the rate of complications or complications specifically for the subgroup of patients with early-stage low-grade tumors. Conclusion In patients with early-stage low-grade serous ovarian cancer, lymph node assessment should be discussed when counseling for primary surgical staging.
Type of Medium:
Online Resource
ISSN:
1048-891X
,
1525-1438
DOI:
10.1136/ijgc-2022-003618
DOI:
10.1136/ijgc-2022-003618.supp1
DOI:
10.1136/ijgc-2022-003618.supp2
Language:
English
Publisher:
BMJ
Publication Date:
2022
detail.hit.zdb_id:
2009072-9
